Investor Presentaiton

For personal use only PSMA-PET imaging emerging as standard of care in prostate cancer Inclusion in guidelines is driving clinical adoption and reimbursement • National Comprehensive Cancer Network Guidelines® (NCCN Guidelines) include Ga-68 PSMA-11 PET/CT to be considered as an alternative to standard imaging of bone and soft tissue 1 • • Conventional imaging no longer a necessary prerequisite to PSMA-PET Aligns with indication for detection of unfavourable intermediate, high and very high risk as well as recurrent prostate cancer Society of Nuclear Medicine and Molecular Imaging (SNMMI) updated Appropriate Use Criteria (AUC) recognises higher accuracy in the initial staging evaluation² Two of the four main Radiology Benefit Managers (RBMS) - AIM Specialty Health³ and NIA Magellan - are now recommending PSMA-PET representing a significant portion of commercial payor (health insurance) reimbursement policies National Comprehensive NCCN Cancer SNMMI Releases New Appropriate Use Criteria: PSMA PET Imaging for Prostate Cancer NetworkⓇ AIM Specialty Health NIA Magellan.. TELIX PHARMACEUTICALS 1. 2. 3. 4. NCCNⓇ Prostate Cancer Guidelines Update, Version 1.2022 - 10/09/21 SNMMI AUC for PSMA-PET Imaging: https://www.snmmi.org/Clinical Practice/content.aspx?Item Number=38657 AIM Clinical Appropriateness Guidelines, Advanced Imaging. AUC: Oncologic Imaging (Effective 7/11/21). National Imaging Associates Magellan Clinical Guidelines For Medical Necessity Review, Advanced Imaging Guideline (Effective 01/01/22) Telix Pharmaceuticals Limited (ASX: TLX) 25

View entire presentation